Future Developments in the Treatment of AL Amyloidosis
Round 1
Reviewer 1 Report
This is a complete review of the literature currently available on the subject and provides some useful clinical pathways in the practical management of AL Amyloidosis and highlighted the limits of current therapies in some subsets of patients
The literature reported includes the most recent studies about this issue and suggest potential strategies for optimal vaccine response.
Author Response
Thank you for your comments.
Reviewer 2 Report
The manuscript is fine, I only have two comments:
Authors should also mention rituximab and BTK inhibitors.
Please try to include a few more diagrams to illustrate the related signaling pathway in AL amyloidosis.
Author Response
Thank you for your comments
Comments 1: Response is included in the revised manuscript
Comments 2: Kindly find in the attached Word two figures regarding signaling pathways in AL amyloidosis
Author Response File: Author Response.pdf
Reviewer 3 Report
Excellent review.
The paper still contains some spelling errors.
For example:
- Intro line 3: from the clonal...
- 2.4. cevostamabr instead of cevostamab
- 2.5. Car instead of CAR-T
Author Response
Spelling errors have been corrected in the revised manuscript.
Thank you for your comments